March 2025 – Page 12

This deal represents a major expansion of Roche’s obesity drug pipeline and a significant partnership in the competitive weight loss medication market.

Gilead hops straight to Phase III with once-yearly HIV PrEP shot

3 months ago talkbio0Tagged formulations, once-yearly, PREP gene, Trial Phase

PREP gene, formulations, once-yearly, Trial Phase

Insilico secures $110M in new funding for AI-designed pipeline

3 months ago talkbio0Tagged Aortic Valve Insufficiency, Clinical Trials

Clinical Trials, Aortic Valve Insufficiency

Merck’s HIV Combo Treatment Advances Towards FDA Filing

3 months ago talkbio0Tagged DOR/ISL, doravirine/islatravir, once-daily, oral regimen, Phase 3 trials, Submission, United States Food and Drug Administration, viral suppression

Doravirine/islatravir (DOR/ISL) combination, Phase 3 trials, Viral suppression, Once-daily oral regimen, FDA submission

Ono Pharmaceutical Acquires Global Rights to Ionis’ Sapablursen for Polycythemia Vera in $940M Deal

3 months ago talkbio0Tagged Dosage Forms, licensing agreement, Polycythemia, RNA-targeted medicine, Sapablursen, vera

Ono Pharmaceutical, Ionis Pharmaceuticals, sapablursen, polycythemia vera, licensing agreement, RNA-targeted medicine

Pharmaceutical Giants Mallinckrodt and Endo Explore $7 Billion Merger

3 months ago talkbio0Tagged Endo, Endometriosis, mallinckrodt, Medical Specialities, Opioid Crisis, pharmaceutical companies, Pharmaceutical merger, Post-bankruptcy consolidation

Pharmaceutical merger, Mallinckrodt, Endo, $7 billion deal, Specialty pharmaceutical companies, Post-bankruptcy consolidation, Opioid crisis fallout